FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Chih-Hsin Yang

Research Profile

Disorders

Chemicals & Drugs

Physiology

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Genes & Molecular Sequences

Genes, erbB-1

Co-author Network

Publications

TOP 3
Tzu-Hsiu Tsai; Pin-Fei Wei; Chen-Tu Wu; Shang-Gin Wu; Chih-Hsin Yang; Pan-Chyr Yang; Chong-Jen Yu; Yih-Leong Chang; Meng-Feng Tsai; Jin-Yuan Shih
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Kuei-Pin Chung; Yen-Tsung Huang; Jin-Yuan Shih; Chih-Hsin Yang; Yeun-Chung Chang; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang
Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chia-Lin Hsu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen Yu; Pan-Chyr Yang
Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Chih-Hsin Yang (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Tzu-Hsiu Tsai; Pin-Fei Wei; Chen-Tu Wu; Shang-Gin Wu; Chih-Hsin Yang; Pan-Chyr Yang; Chong-Jen Yu; Yih-Leong Chang; Meng-Feng Tsai; Jin-Yuan Shih
Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2012;7(6):993-1000.
2012: Kuei-Pin Chung; Yen-Tsung Huang; Jin-Yuan Shih; Chih-Hsin Yang; Yeun-Chung Chang; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang
Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chest 2012;141(2):420-8.
2012: Chia-Lin Hsu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen Yu; Pan-Chyr Yang
Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors.
BMC cancer 2012;12():241.
2012: Zhong-Zhe Lin; Yu-Yun Shao; Chih-Hsin Yang; Dwan-Ying Chang; Ruey-Long Hong; Chiun Hsu; Chih-Hung Hsu; Fu-Chang Hu; Ann-Lii Cheng
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy.
The oncologist 2012;17(7):970-7.
2011: Chung-Yu Chen; Kuan-Yu Chen; Jou-Wei Lin; Jin-Yuan Shih; Chih-Hsin Yang; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
Lung cancer (Amsterdam, Netherlands) 2011;74(1):132-8.
2011: Jenn-Yu Wu; Chong-Jen Yu; Yeun-Chung Chang; Chih-Hsin Yang; Jin-Yuan Shih; Pan-Chyr Yang
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(11):3812-21.
2011: Shang-Gin Wu; Chih-Hsin Yang; Chong-Jen Yu; Jih-Hsiang Lee; Ya-Chieh Hsu; Yih-Leong Chang; Jin-Yuan Shih; Pan-Chyr Yang
Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations.
Lung cancer (Amsterdam, Netherlands) 2011;72(3):333-9.
2011: Jenn-Yu Wu; Jin-Yuan Shih; Kuan-Yu Chen; Chih-Hsin Yang; Chong-Jen Yu; Pan-Chyr Yang
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.
Medicine 2011;90(3):159-67.
2011: Jenn-Yu Wu; Shang-Gin Wu; Chih-Hsin Yang; Yih-Leong Chang; Yeun-Chung Chang; Ya-Chieh Hsu; Jin-Yuan Shih; Pan-Chyr Yang
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Lung cancer (Amsterdam, Netherlands) 2011;72(2):205-12.
2010: Chia-Chi Lin; Hsin-Hsin Hsu; Chia-Tung Sun; Jin-Yuan Shih; Zhong-Zhe Lin; Chong-Jen Yu; George G Chen; Michael Kuan Yew Hsin; Kwok Chi Lam; Linda Leung; Chih-Hsin Yang; Tony Shu Kam Mok
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(9):1424-9.
2010: Jenn-Yu Wu; Chih-Hsin Yang; Ya-Chieh Hsu; Chong-Jen Yu; Shih-Han Chang; Jin-Yuan Shih; Pan-Chyr Yang
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
Clinical lung cancer 2010;11(4):257-63.
2010: Yu-Yun Shao; Chia-Chi Lin; Chih-Hsin Yang
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Discovery medicine 2010;9(49):538-45.
2010: Pei-Fang Wu; Kuan-Ting Kuo; Lu-Ting Kuo; Yi-Ting Lin; Wei-Chung Lee; Yen-Shen Lu; Chih-Hsin Yang; Ruey-Meei Wu; Yong-Kwang Tu; Jui-Chang Tasi; Ham-Min Tseng; Sheng-Hong Tseng; Ann-Lii Cheng; Ching-Hung Lin
O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers.
Lung cancer (Amsterdam, Netherlands) 2010;68(3):484-90.
2010: Yu-Yun Shao; Fu-Chang Hu; Jin-Tung Liang; Wen-Tzu Chiu; Ann-Lii Cheng; Chih-Hsin Yang
Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
Journal of the Formosan Medical Association = Taiwan yi zhi 2010;109(5):362-8.
2010: Jih-Hsiang Lee; Chong-Jen Yu; Kuan-Yu Chen; Jin-Yuan Shih; Yu-Lin Lin; Chih-Hsin Yang
Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer.
Journal of the Formosan Medical Association = Taiwan yi zhi 2010;109(5):338-44.
2010: Chih-Hsin Yang; Lorinda Simms; Keunchil Park; Jin Soo Lee; Giorgio Scagliotti; Mauro Orlando
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(5):688-95.
2010: Jenn-Yu Wu; Chong-Jen Yu; Jin-Yuan Shih; Chih-Hsin Yang; Pan-Chyr Yang
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2010;67(3):348-54.
2010: Chun-Ta Huang; Rouh-Fang Yen; Mei-Fang Cheng; Ya-Chieh Hsu; Pin-Fei Wei; Yi-Ju Tsai; Meng-Feng Tsai; Jin-Yuan Shih; Chih-Hsin Yang; Pan-Chyr Yang
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Medical oncology (Northwood, London, England) 2010;27(1):9-15.
2010: Kuan-Yu Chen; Jen-Hau Chen; Jin-Yuan Shih; Chih-Hsin Yang; Chong-Jen Yu; Pan-Chyr Yang
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(1):82-9.
2010: Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen Yu; Pan-Chyr Yang
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
International journal of cancer. Journal international du cancer 2010;126(1):247-55.
2009: Chin-Lun Huang; Chih-Hsin Yang; Kun-Huei Yeh; Fu-Chang Hu; Kuan-Yu Chen; Jin-Yuan Shih; Zhong-Zhe Lin; Chong-Jen Yu; Ann-Lii Cheng; Pan-Chyr Yang
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.
Lung cancer (Amsterdam, Netherlands) 2009;64(3):346-51.
2009: Chia-Chi Lin; Chih-Hsin Yang
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Targeted oncology 2009;4(1):37-44.
2008: Shang-Gin Wu; Yih-Leong Chang; Ya-Chieh Hsu; Jenn-Yu Wu; Chih-Hsin Yang; Chong-Jen Yu; Meng-Feng Tsai; Jin-Yuan Shih; Pan-Chyr Yang
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
The oncologist 2008;13(12):1276-84.
2008: Chiun Hsu; Sow-Hsong Kuo; Fu-Chang Hu; Ann-Lii Cheng; Jin-Yuan Shih; Chong-Jen Yu; Chia-Chi Lin; Tsu-Chen Huang; Pan-Chyr Yang; Chih-Hsin Yang
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Lung cancer (Amsterdam, Netherlands) 2008;62(3):334-43.
2008: Chia-Chi Lin; Yeong-Shiau Pu; Chih-Hung Hsu; Hsiao-Yi Keng; Ann-Lii Cheng; Chih-Hsin Yang
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma.
Urologic oncology 2008;26(6):659-61.
2008: Jenn-Yu Wu; Chong-Jen Yu; Chih-Hsin Yang; Shang-Gin Wu; Yueh-Hsia Chiu; Chien-Hung Gow; Yeun-Chung Chang; Ya-Chieh Hsu; Pin-Fei Wei; Jin-Yuan Shih; Pan-Chyr Yang
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
American journal of respiratory and critical care medicine 2008;178(8):847-53.
2008: S-G Wu; Chien-Hung Gow; Chong-Jen Yu; Yih-Leong Chang; Chih-Hsin Yang; Y-C Hsu; Jin-Yuan Shih; Yung-Chie Lee; Pan-Chyr Yang
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma.
The European respiratory journal 2008;32(4):924-30.
2008: Jenn-Yu Wu; Shang-Gin Wu; Chih-Hsin Yang; Chien-Hung Gow; Yih-Leong Chang; Chong-Jen Yu; Jin-Yuan Shih; Pan-Chyr Yang
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(15):4877-82.
2008: Chih-Hsin Yang
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Lung cancer (Amsterdam, Netherlands) 2008;60 Suppl 2():S23-30.
2008: Chih-Hsin Yang; Chong-Jen Yu; Jin-Yuan Shih; Yeun-Chung Chang; Fu-Chang Hu; Meng-Chin Tsai; Kuan-Yu Chen; Zhong-Zhe Lin; Ching-Ju Huang; Chia-Tung Shun; Chin-Lun Huang; James Bean; Ann-Lii Cheng; William Pao; Pan-Chyr Yang
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2745-53.
2008: Zhong-Zhe Lin; Chiun Hsu; Yeun-Chung Chang; Chong-Jen Yu; Chih-Hung Hsu; Chia-Chi Lin; Ann-Lii Cheng; Pan-Chyr Yang; Chih-Hsin Yang
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.
Lung cancer (Amsterdam, Netherlands) 2008;60(2):215-21.
2008: Jo-Pai Chen; Yin Lo; Chong-Jen Yu; Chiun Hsu; Jin-Yuan Shih; Chih-Hsin Yang
Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers.
Lung cancer (Amsterdam, Netherlands) 2008;60(1):92-7.
2008: Chien-Hung Gow; Chun-Ru Chien; Yih-Leong Chang; Yueh-Hsia Chiu; Sow-Hsong Kuo; Jin-Yuan Shih; Yeun-Chung Chang; Chong-Jen Yu; Chih-Hsin Yang; Pan-Chyr Yang
Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):162-8.
2008: Chao-Chi Ho; Sow-Hsong Kuo; Pei-Hsin Huang; Hsin-Yi Huang; Chih-Hsin Yang; Pan-Chyr Yang
Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2008;59(1):105-10.
2007: Chia-Chi Lin; Kun-Huei Yeh; Chih-Hsin Yang; Chiun Hsu; Yu-Chieh Tsai; Wei-Ling Hsu; Ann-Lii Cheng; Chih-Hung Hsu
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Anti-cancer drugs 2007;18(6):703-8.
2007: Chia-Chi Lin; Chiun Hsu; Chih-Hung Hsu; Wei-Ling Hsu; Ann-Lii Cheng; Chih-Hsin Yang
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.
Investigational new drugs 2007;25(1):77-84.
2007: Chia-Chi Lin; Ann-Lii Cheng; Chih-Hung Hsu; Yen-Shen Lu; Chiun Hsu; Kun-Huei Yeh; Chen-Yao Wu; Chiun-Sheng Huang; Chih-Hsin Yang
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.
Anticancer research 2007;27(1B):641-5.
2006: Chih-Hsin Yang; Jin-Yuan Shih; Kun-Chieh Chen; Chong-Jen Yu; Tsung-Ying Yang; Ching-Pei Lin; Wen-Pin Su; Chien-Hung Gow; Chiun Hsu; Gee-Chen Chang; Pan-Chyr Yang
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Cancer 2006;107(8):1873-82.
2006: Jin-Yuan Shih; Chien-Hung Gow; Chong-Jen Yu; Chih-Hsin Yang; Yih-Leong Chang; Meng-Feng Tsai; Ya-Chieh Hsu; Kuan-Yu Chen; Wen-Pin Su; Pan-Chyr Yang
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
International journal of cancer. Journal international du cancer 2006;118(4):963-9.
2005: Wen-Pin Su; Chih-Hsin Yang; Chong-Jen Yu; Jin-Yuan Shih; Chiun Hsu; Pan-Chyr Yang
Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.
Journal of the Formosan Medical Association = Taiwan yi zhi 2005;104(8):557-62.
2005: Chih-Hsin Yang; Ching-Ju Huang; Chao-Shun Yang; Yu-Chuan Chu; Ann-Lii Cheng; Jacqueline Whang-Peng; Pan-Chyr Yang
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Cancer research 2005;65(15):6943-9.
2005: Sow-Hsong Kuo; Chih-Hsin Yang; Chong-Jen Yu; Chiun Hsu; Ann-Lii Cheng; Pan-Chyr Yang
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials.
Lung cancer (Amsterdam, Netherlands) 2005;48(2):275-80.
2005: Chih-Hsin Yang; MIN-CHUN CHEN; Ann-Lii Cheng; Chih-Hung Hsu; Kun-Huei Yeh; Yu-Chie Yu; Jacqueline Whang-Peng; Pan-Chyr Yang
Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
Oncology 2005;68(4-6):350-5.
2004: Yen-Shen Lu; Chiun Hsu; Chi-Cheng Li; Sow-Hsong Kuo; Kun-Huei Yeh; Chih-Hsin Yang; Chih-Hung Hsu; Chen-Yao Wu; Ann-Lii Cheng
Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Hepato-gastroenterology 2004;51(57):815-9.
2004: Wei-Chu Chie; Chih-Hsin Yang; Chiun Hsu; Pan-Chyr Yang
Quality of life of lung cancer patients: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2004;13(1):257-62.
2003: Chih-Hsin Yang; Yao-Chang Chen; Min-Liang Kuo
Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.
Anticancer research 2003;23(3B):2519-23.
2002: Chih-Hung Hsu; Ann-Lii Cheng; Chiun Hsu; Chih-Hsin Yang; Yen-Shen Lu; Chia-Chi Lin; Ching-Fang Bu; Kun-Huei Yeh
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Anticancer research 2002;22(6B):3621-7.
1999: Chih-Hsin Yang; Ann-Lii Cheng; Kun-Huei Yeh; Chong-Jen Yu; J F Lin; Pan-Chyr Yang
High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma.
Cancer 1999;86(3):415-20.
1998: Ann-Lii Cheng; Kun-Huei Yeh; R L Fine; Shuang-En Chuang; Chih-Hsin Yang; L H Wang; Ding-Shinn Chen
Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Hepato-gastroenterology 1998;45(24):1955-60.